Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Leaderboard Analytics
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
Holwill v. AbbVie Inc. et al
Case Number:
1:18-cv-06790
Court:
Nature of Suit:
Multi Party Litigation:
Class Action
15:78m(a) Securities Exchange Act
Judge:
Firms
- Clifford Law Offices
- Cohen Milstein
- DiCello Levitt
- Gardiner Koch
- Kirby McInerney
- Kirkland & Ellis
- Motley Rice
- Pomerantz LLP
- Robbins Geller
- Wilson Sonsini
Companies
Sectors & Industries:
-
March 18, 2021
AbbVie Loses Judge-Switch Bid In Humira Kickback Battles
AbbVie Inc. lost a bid on Thursday to have a single judge handle a pair of closely watched fraud cases over allegations that the company illegally marketed its drug Humira, with an Illinois federal judge ruling that reassignment would significantly delay a whistleblower's False Claims Act case before her.
-
March 16, 2021
AbbVie Denies Judge-Shopping In Humira Kickback Cases
AbbVie Inc. insisted Tuesday that its push for one judge to handle a pair of closely watched fraud cases has nothing to do with that judge rejecting kickback theories that another judge deemed viable, saying it merely desires consistency.
-
February 02, 2021
Investors Seek Class Cert. In Humira Marketing Suit
A German asset management firm and the Ironworkers National Pension Plan asked an Illinois federal judge Monday to certify a class of investors suing drugmaker AbbVie, arguing all the stockholders relied on the same misstatements and thus would be an efficient fair class.
-
September 02, 2020
AbbVie Can't Escape Investors' Humira Kickbacks Suit
An Illinois federal judge Tuesday refused to toss an AbbVie Inc. investor class action alleging that the pharmaceutical company concealed its use of an illegal strategy to market its blockbuster drug Humira, saying the investors had sufficiently alleged detailed claims of fraud and deceptive intent.
-
November 20, 2019
AbbVie Investors Fight Bid To Toss Humira Kickbacks Suit
Investors urged an Illinois federal judge on Tuesday not to dismiss a lawsuit against AbbVie Inc., saying they've adequately alleged that the pharmaceutical company concealed its use of an illegal strategy to market its blockbuster drug Humira.
-
November 21, 2018
3 Firms Vie To Lead Class Suit Over Alleged AbbVie Kickbacks
Three law firms representing investors suing AbbVie Inc. in a proposed class action over its allegedly illegal strategy to market its blockbuster drug Humira have each asked an Illinois federal judge to appoint it as lead counsel in the case.
-
October 10, 2018
AbbVie Faces 2nd Investor Suit Over Humira Kickbacks
AbbVie Inc. was hit with another proposed class action over its allegedly illegal strategy to market its blockbuster drug Humira, this one filed Tuesday by shareholders in Illinois federal court who say the company's misleading statements caused them huge losses.